PaxMedica's Research on Low Dose Suramin for Autism Spectrum Disorder Accepted for Publication
October 26 2023 - 1:51PM
via IBN -- PaxMedica, Inc. (Nasdaq: PXMD) a clinical-stage
biopharmaceutical company, is excited to announce that the Annals
of General Psychiatry, an internationally recognized scientific
psychiatry publication, has accepted the manuscript titled
"Randomized clinical trial of low dose suramin intravenous
infusions for treatment of autism spectrum disorder" for
publication.
This groundbreaking research, authored by PaxMedica’s Chief
Medical Officer, Dr. David Hough, MD, along with nine co-authors,
highlights the potential of monthly suramin intravenous infusions
as a safe and potentially efficacious treatment for the core
symptoms of Autism Spectrum Disorder (ASD). The co-authors of the
manuscript include Alice Mao MD, Michael Aman Ph.D, Reymundo Lozano
MD MS, Constance Smith-Hicks MD Ph.D, Veronica Martinez-Cerdeno
PH.D, Michael Derby, Zachary Rome, Miel Malan MD, and Robert
Findling MD.
"The acceptance of this manuscript represents a significant
milestone in PaxMedica's continued dedication to pioneering
innovative treatments for Autism Spectrum Disorder. We are honored
to contribute to the field of psychiatry with this significant
research, underscoring our commitment to advancing the
understanding and treatment of ASD," commented Dr. David Hough,
Chief Medical Officer at PaxMedica.
The Annals of General Psychiatry, an open access journal
emphasizing a biopsychosocial approach to illness and health,
strongly supports the principles of evidence-based medicine,
further validating the significance of this research.
As the manuscript progresses toward publication, PaxMedica
extends its gratitude to the Annals of General Psychiatry for their
support in sharing this essential research with the global
scientific community.
For further updates and information, please visit PaxMedica's
official website at www.paxmedica.com.
About PaxMedica
PaxMedica, Inc. is a forward-looking clinical-stage
biopharmaceutical firm specializing in cutting-edge anti-purinergic
drug therapies (APT) designed to address challenging neurologic
disorders. Our scope encompasses a spectrum of conditions, from
neurodevelopmental disorders, including Autism Spectrum Disorder
(ASD), to the debilitating Myalgic Encephalomyelitis/Chronic
Fatigue Syndrome (ME/CFS), marked by both physical and cognitive
burdens. At PaxMedica, we prioritize the advancement and evaluation
of our flagship program, PAX-101—an intravenous suramin
formulation—primarily focused on ASD treatment, while also
broadening our clinical insights into its potential applications
for conditions such as ME/CFS. For more information,
visit www.paxmedica.com.
Interested investors and shareholders are encouraged to sign up
for press releases and industry updates by registering for Email
Alerts at https://www.paxmedica.com/email-alerts and by
following PaxMedica
on Twitter and LinkedIn.
Forward-Looking Statements
This press release contains “forward-looking statements.”
Forward-looking statements reflect our current view about future
events. Investors can identify these forward-looking statements by
words or phrases such as “may,” “will,” “could,” “expect,”
“anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,”
“is/are likely to,” “propose,” “potential,” “continue” or similar
expressions. These forward-looking statements include our
anticipated clinical program, the timing and success of our
anticipated data announcements, pre-clinical and clinical trials
and regulatory filings, statements about the strength of our
balance sheet. These forward-looking statements involve known and
unknown risks and uncertainties and are based on the Company’s
current expectations and projections about future events that the
Company believes may affect its financial condition, results of
operations, business strategy and financial needs. Such risks and
uncertainties include, but are not limited to, risks associated
with the Company’s development work, including any delays or
changes to the timing, cost and success of the Company’s product
development and clinical trials, risk of insufficient capital
resources, cash funding and cash burn and risks associated with
intellectual property and infringement claims. The Company
undertakes no obligation to update or revise publicly any
forward-looking statements to reflect subsequent occurring events
or circumstances, or changes in its expectations, except as may be
required by law. Although the Company believes that the
expectations expressed in these forward-looking statements are
reasonable, it cannot assure you that such expectations will turn
out to be correct, and the Company cautions investors that actual
results may differ materially from the anticipated results and
encourages investors to review other factors that may affect its
future results described in the Company’s “Risk Factors” section
and other sections in its most recent Annual Report on Form 10-K,
and subsequent quarterly and other filings with the U.S. Securities
and Exchange Commission.
Contacts
PaxMedica, Inc. 303 S Broadway, Suite 125.
Tarrytown, NY 10591 www.paxmedica.com
Media Contact media@paxmedica.com
Investor Contact Scott McGowan
InvestorBrandNetwork (IBN) Phone: 310.299.1717
PaxMedica (NASDAQ:PXMD)
Historical Stock Chart
From Apr 2024 to May 2024
PaxMedica (NASDAQ:PXMD)
Historical Stock Chart
From May 2023 to May 2024